Scientists and legislative activists will meet Tuesday night to discuss the current state of the use of psychedelic substances to treat mental health conditions.

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The move expands access to the novel mental health treatment, which has shown rapid symptom improvement for the past few ...

The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...

First patient treated in Phase II portion of clinical trial in metastatic prostate cancer at the West Los Angeles Veterans Administration ...

Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance last spring.

The scientific literature has highlighted the role of inflammation in major depressive disorder (MDD), permeating several states of the disease. In chronic ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...